Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lumos Pharma Inc (NQ: LUMO )

4.370 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lumos Pharma Inc

< Previous 1 2 3 4 Next >
Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?
Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all... 
Via Benzinga
Roblox, Under Armour, GoPro, Nuvei And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 20 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
What 7 Analyst Ratings Have To Say About Lumos Pharma
Via Benzinga
The Latest Analyst Ratings for Lumos Pharma
Via Benzinga
Lumos Pharma: Q1 Earnings Insights
Via Benzinga
Why American Public Education Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) shares surged 332% to $0.6455 in pre-market trading after falling over 7% on Tuesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're starting the morning with a breakdown of the biggest ones. 
Via InvestorPlace
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
Phase 2 Data Provide Supportive Evidence to Advance Oral LUM-201 to Phase 3 
From Lumos Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Participation in Investor Conferences in September
From Lumos Pharma, Inc.
Via GlobeNewswire
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
Virtual Webinar to be held September 5, 2023, at 11:00 AM Eastern Time 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
From Lumos Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Lumos Pharma Announces Departure of Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in the Upcoming 2023 BIO International Convention and the Jefferies Healthcare Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Announces Abstracts Accepted for Oral Presentation at 2023 ENDO Meeting with Virtual KOL Event to be Held on June 21st
KOL Webinar to be held June 21, 2023 at 11:00 AM Eastern Time 
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in World Orphan Drug Congress USA
From Lumos Pharma, Inc.
Via GlobeNewswire
Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma Reports First Quarter 2023 Financial Results, Provides Clinical Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.